Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Piperazines Stories

2012-12-14 08:24:42

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Dec. 14, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending that ADASUVE (Staccato loxapine) be granted European Union (EU) centralized marketing authorization. The CHMP recommends that ADASUVE be authorized in the EU for the rapid control of...

2012-12-12 16:24:53

DEERFIELD, Ill., Dec. 12, 2012 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients. According to the timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the NDA is targeted...

2012-12-10 16:24:12

EAST HANOVER, N.J., Dec. 10, 2012 /PRNewswire/ -- The latest results from two Phase III clinical trials further establish the benefits of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to Tasigna after long-term treatment with Gleevec. Findings from both studies were presented in oral sessions...

2012-12-10 16:55:13

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair. Now,...

2012-12-10 16:41:33

Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have provided unprecedented opportunities for the...

2012-12-09 08:20:16

ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have...

2012-11-29 14:56:43

HOUSTON — A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine. All 12 patients in the trial with chronic phase CML and the T315I mutation had a complete hematologic response (absence of CML cells in the blood) after treatment with ponatinib. Eleven had a major reduction in CML cells in the bone marrow and nine achieved a...

2012-11-28 11:18:28

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications — schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs. In a new study — led by researchers at the University of California, San...

2012-11-15 12:28:02

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- A variety of medical conditions and treatments can contribute to erectile dysfunction (ED). After robotic prostate surgery, it is common for men to experience short-term sexual potency issues. Dr. David Samadi's SMART (Samadi Modified Advanced Robotic Technique) robotic surgery greatly reduces the risk of nerve bundle damage and delivers superior prostate cancer treatment results. (Photo: http://photos.prnewswire.com/prnh/20121115/NY13851 ) To...

2012-10-30 07:26:50

INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved Cialis 5 mg for once daily use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis was approved for erectile dysfunction (ED) in the EU in 2002. Cialis for once daily use was approved to treat ED in the EU in 2007. "With this approval, Cialis is now the only medication in the EU to provide a single treatment option for...